Abstract
New treatments for patients with Waldenstrom's macroglobulinemia (WM) have necessited the development of prognostic indices. Using a sample of 92 patients with refractory or relapsing WM treated in a randomized trial, we show that Morel's prognostic scoring system for patients at diagnosis is also effective in patients with advanced disease.
Vol. 90 No. 2 (2005): February, 2005 : Letters to the Editor
Published By
Ferrata Storti Foundation, Pavia, Italy
Statistics from Altmetric.com
